Patient-centred Preferences for Biologic Therapies in Moderate to Severe Psoriasis in Vietnam: A Discrete Choice Experiment
DOI:
https://doi.org/10.2340/actadv.v105.42840Keywords:
Psoriasis, Biologics, patient preferences, decision makingAbstract
Psoriasis is a chronic autoimmune disease that significantly impairs patients’ quality of life. With the growing availability of biologic drugs – each varying in efficacy, safety, dosing, and cost – treatment decisions have become increasingly complex. A study conducted from March to July 2024 surveyed 302 Vietnamese patients with moderate to severe psoriasis to assess preferences for biologic therapies. Using a discrete choice experiment (DCE), participants evaluated 6 treatment attributes: short-term efficacy, long-term efficacy, sustained efficacy after drug withdrawal, frequency of administration, copayment, and risk of serious infection. Preference data were analysed using conditional logit models. Analysis revealed that treatment cost (relative importance [RI]: 31.4%) and long-term efficacy (RI: 25.3%) were the most critical factors influencing patient decisions, while sustained efficacy after withdrawal and early onset of efficacy were less impactful. Long-term efficacy and cost consistently ranked highest across all patient subgroups, with variations depending on demographic and clinical characteristics. These findings provide practical guidance for clinicians to incorporate patient preferences into the selection of biologic therapies, with particular emphasis on treatment cost and long-term efficacy. The significant influence of treatment cost also highlights the need for healthcare policymakers in Vietnam to enhance reimbursement policies and financial support programmes, improving access and equity in psoriasis care.
Downloads
References
Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of psoriasis and comorbid diseases: a narrative review. Front Immunol 2022; 13: 880201.
https://doi.org/10.3389/fimmu.2022.880201 DOI: https://doi.org/10.3389/fimmu.2022.880201
Damiani G, Bragazzi NL, Karimkhani Aksut C, Wu D, Alicandro G, McGonagle D, et al. The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 Study. Front Med (Lausanne) 2021; 8: 743180.
https://doi.org/10.3389/fmed.2021.743180 DOI: https://doi.org/10.3389/fmed.2021.743180
Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, -Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020; 369: m1590.
https://doi.org/10.1136/bmj.m1590 DOI: https://doi.org/10.1136/bmj.m1590
Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386: 983–994.
https://doi.org/10.1016/s0140-6736(14)61909-7 DOI: https://doi.org/10.1016/S0140-6736(14)61909-7
Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 Suppl 2: ii18–23; discussion ii24–25.
https://doi.org/10.1136/ard.2004.033217 DOI: https://doi.org/10.1136/ard.2004.033217
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021; 35: 281–317.
https://doi.org/10.1111/jdv.16926 DOI: https://doi.org/10.1111/jdv.16926
Smith CH, Yiu ZZN, Bale T, Burden AD, Coates Laura C, Eckert E, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023: a pragmatic update. Br Jo Dermatol 2023; 190: 270–272.
https://doi.org/10.1093/bjd/ljad347 DOI: https://doi.org/10.1093/bjd/ljad347
Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis 2024; 83: 706–719. DOI: https://doi.org/10.1136/ard-2024-225534
https://doi.org/10.1136/ard-2024-225531 DOI: https://doi.org/10.1136/ard-2024-225531
Lecluse LL, Tutein Nolthenius JL, Bos JD, Spuls PI. Patient preferences and satisfaction with systemic therapies for psoriasis: an area to be explored. Br J Dermatol 2009; 160: 1340–1343.
https://doi.org/10.1111/j.1365-2133.2009.09115.x DOI: https://doi.org/10.1111/j.1365-2133.2009.09115.x
Umar N, Schaarschmidt M, Schmieder A, Peitsch WK, Schöllgen I, Terris DD. Matching physicians’ treatment recommendations to patients’ treatment preferences is associated with improvement in treatment satisfaction. J Eur Acad Dermatol Venereol 2013; 27: 763–770.
https://doi.org/10.1111/j.1468-3083.2012.04569.x DOI: https://doi.org/10.1111/j.1468-3083.2012.04569.x
Tsai T-F, Ho J-C, Chen Y-J, Hsiao P-F, Lee W-R, Chi C-C, et al. Health-related quality of life among patients with moderate-to-severe plaque psoriasis in Taiwan. Dermatologica Sinica 2018; 36: 190–195.
https://doi.org/10.1016/j.dsi.2018.06.006 DOI: https://doi.org/10.1016/j.dsi.2018.06.006
Umar N, Litaker D, Schaarschmidt ML, Peitsch WK, Schmieder A, Terris DD. Outcomes associated with matching patients’ treatment preferences to physicians’ recommendations: study methodology. BMC Health Serv Res 2012; 12: 1.
https://doi.org/10.1186/1472-6963-12-1 DOI: https://doi.org/10.1186/1472-6963-12-1
Nguyen HT, Pham NTU, Tran TNA, Pham NN, Bui YT, Vu TTP. Long-term effectiveness and drug survival of secukinumab in Vietnamese patients with psoriasis: results from a retrospective ENHANCE Study. Dermatol Ther (Heidelb) 2023; 13: 465–476.
https://doi.org/10.1007/s13555-022-00867-y DOI: https://doi.org/10.1007/s13555-022-00867-y
Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics 2014; 32: 883–902.
https://doi.org/10.1007/s40273-014-0170-x DOI: https://doi.org/10.1007/s40273-014-0170-x
Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health – a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011; 14: 403–413.
https://doi.org/10.1016/j.jval.2010.11.013 DOI: https://doi.org/10.1016/j.jval.2010.11.013
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris – Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 2020; 34: 2461–2498.
https://doi.org/10.1111/jdv.16915 DOI: https://doi.org/10.1111/jdv.16915
Johnson FR, Ozdemir S, Phillips KA. Effects of simplifying choice tasks on estimates of taste heterogeneity in stated-choice surveys. Soc Sci Med 2010; 70: 183–190.
https://doi.org/10.1016/j.socscimed.2009.10.021 DOI: https://doi.org/10.1016/j.socscimed.2009.10.021
Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health 2013; 16: 3–13.
https://doi.org/10.1016/j.jval.2012.08.2223 DOI: https://doi.org/10.1016/j.jval.2012.08.2223
Hauber AB, González JM, Groothuis-Oudshoorn CG, Prior T, Marshall DA, Cunningham C, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health 2016; 19: 300–315.
https://doi.org/10.1016/j.jval.2016.04.004 DOI: https://doi.org/10.1016/j.jval.2016.04.004
Lang Y, Wu B, Sun Z, Ye E, Dou G, Guan X. Patient preference for biologic treatments of psoriasis in the Chinese setting. Patient Prefer Adherence 2022; 16: 1071–1084.
https://doi.org/10.2147/ppa.S357795 DOI: https://doi.org/10.2147/PPA.S357795
Tada Y, Ishii K, Kimura J, Hanada K, Kawaguchi I. Patient preference for biologic treatments of psoriasis in Japan. J -Dermatol 2019; 46: 466–477.
https://doi.org/10.1111/1346-8138.14870 DOI: https://doi.org/10.1111/1346-8138.14870
Schaarschmidt ML, Schmieder A, Umar N, Terris D, -Goebeler M, Goerdt S, et al. Patient preferences for psoriasis -treatments: process characteristics can outweigh outcome attributes. Arch Dermatol 2011; 147: 1285–1294.
https://doi.org/10.1001/archdermatol.2011.309 DOI: https://doi.org/10.1001/archdermatol.2011.309
Komine M, Kim H, Yi J, Zhong Y, Sakai Y, Crawford B, et al. A discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients in Japan. J Dermatol 2023; 50: 766–777.
https://doi.org/10.1111/1346-8138.16746 DOI: https://doi.org/10.1111/1346-8138.16746
Gorelick J, Shrom D, Sikand K, Renda L, Burge R, Dworkin C, et al. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey. Dermatol Ther (-Heidelb) 2019; 9: 785–797.
https://doi.org/10.1007/s13555-019-00334-1 DOI: https://doi.org/10.1007/s13555-019-00334-1
Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol 2007; 143: 1175–1179.
https://doi.org/10.1001/archderm.143.9.1175 DOI: https://doi.org/10.1001/archderm.143.9.1175
Bolt T, Kobayashi H, Mahlich J. Patient and physician preferences for therapy characteristics for psoriasis: a discrete choice experiment in Japan. Pharmacoecon Open 2019; 3: 255–264.
https://doi.org/10.1007/s41669-018-0104-1 DOI: https://doi.org/10.1007/s41669-018-0104-1
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Chuyen Thi Hong Nguyen, Xuan Thi Mai Nguyen, Trung The Van
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
